MA46041A - Anticorps anti-tim -3 - Google Patents

Anticorps anti-tim -3

Info

Publication number
MA46041A
MA46041A MA046041A MA46041A MA46041A MA 46041 A MA46041 A MA 46041A MA 046041 A MA046041 A MA 046041A MA 46041 A MA46041 A MA 46041A MA 46041 A MA46041 A MA 46041A
Authority
MA
Morocco
Prior art keywords
tim
body anti
Prior art date
Application number
MA046041A
Other languages
English (en)
Inventor
Carmine Carpenito
Yiwen Li
Yang Shen
Yi Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA46041A publication Critical patent/MA46041A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA046041A 2016-08-25 2017-08-17 Anticorps anti-tim -3 MA46041A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662379343P 2016-08-25 2016-08-25
US201762469753P 2017-03-10 2017-03-10

Publications (1)

Publication Number Publication Date
MA46041A true MA46041A (fr) 2021-03-24

Family

ID=59772703

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046041A MA46041A (fr) 2016-08-25 2017-08-17 Anticorps anti-tim -3

Country Status (26)

Country Link
US (1) US10253096B2 (fr)
EP (1) EP3504240B1 (fr)
JP (1) JP6502590B1 (fr)
KR (1) KR102142903B1 (fr)
CN (1) CN109563172B (fr)
AU (1) AU2017316473B2 (fr)
BR (1) BR112019001589A2 (fr)
CA (1) CA3035042A1 (fr)
CL (1) CL2019000488A1 (fr)
CO (1) CO2019001646A2 (fr)
CR (1) CR20190079A (fr)
DO (1) DOP2019000027A (fr)
EC (1) ECSP19013181A (fr)
ES (1) ES2908916T3 (fr)
IL (1) IL264159A (fr)
JO (1) JOP20190013A1 (fr)
MA (1) MA46041A (fr)
MX (1) MX2019002064A (fr)
PE (1) PE20190630A1 (fr)
PH (1) PH12019500369A1 (fr)
SG (1) SG11201900480YA (fr)
TN (1) TN2019000040A1 (fr)
TW (2) TWI639616B (fr)
UA (1) UA122929C2 (fr)
WO (1) WO2018039020A1 (fr)
ZA (1) ZA201900373B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2980390A1 (fr) 2015-03-23 2016-09-29 Bayer Pharma Aktiengesellschaft Anticorps anti-ceacam6 et leurs utilisations
PL3443009T3 (pl) 2016-04-12 2022-01-31 Symphogen A/S Przeciwciała i kompozycje anty-tim-3
JP7027401B2 (ja) 2016-07-14 2022-03-01 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
EP3551659A1 (fr) * 2016-12-08 2019-10-16 Eli Lilly and Company Anticorps anti-tim-3 pour combinaison avec des anticorps anti-pd-l1
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
CA3185303A1 (fr) 2017-04-05 2018-10-11 Symphogen A/S Polytherapies ciblant pd-1, tim-3 et lag-3
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
US11807683B2 (en) 2018-04-12 2023-11-07 Nanjing Leads Biolabs Co., Ltd. Antibody binding TIM-3 and use thereof
WO2020043095A1 (fr) * 2018-08-28 2020-03-05 江苏恒瑞医药股份有限公司 Composition pharmaceutique d'anticorps anti-tim3 et son utilisation
JP2022505925A (ja) * 2018-11-01 2022-01-14 メルク パテント ゲーエムベーハー 抗ｔｉｍ－３抗体
AU2019372436A1 (en) * 2018-11-01 2021-05-20 Merck Patent Gmbh Methods of administering anti-TIM-3 antibodies
EP3897844B1 (fr) 2018-12-19 2023-11-15 Deutsches Krebsforschungszentrum Combinaison pharmaceutique des anticoprs anti-ceacam6 et anti-tim3
WO2020146196A1 (fr) 2019-01-11 2020-07-16 Eli Lilly And Company Anticorps de tim-3 et combinaisons avec d'autres inhibiteurs de points de contrôle pour le traitement du cancer
WO2020243563A1 (fr) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Signatures géniques multi-tumorales destinées à être adaptées à une thérapie immuno-oncologique
WO2020243568A1 (fr) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Procédés d'identification d'un sujet approprié pour une thérapie d'immuno-oncologie (i-o)
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
WO2021051352A1 (fr) * 2019-09-19 2021-03-25 上药生物治疗（香港）有限公司 Protéine de liaison à l'antigène isolée et son utilisation
US11396647B2 (en) 2020-01-07 2022-07-26 Board Of Regents, The University Of Texas System Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
WO2022146947A1 (fr) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Compositions d'anticorps et leurs procédés d'utilisation
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
US20240368280A1 (en) 2021-09-02 2024-11-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects
JP2025509749A (ja) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
EP4531916A1 (fr) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Compositions d'anticorps et leurs procédés d'utilisation
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
EP3020413A1 (fr) 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Compositions et procédés liés à TIM-3, molécule de surface cellulaire spécifique à TH1
WO2010117057A1 (fr) * 2009-04-10 2010-10-14 協和発酵キリン株式会社 Procédé pour le traitement d'une tumeur sanguine utilisant un anticorps anti-tim-3
ES2682078T3 (es) 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
AU2015287969B2 (en) 2014-07-07 2020-07-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
CA2965960A1 (fr) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anticorps anti-tim -3
GB201419094D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
PL3215532T3 (pl) * 2014-11-06 2020-03-31 F. Hoffmann-La Roche Ag Przeciwciała anty-TIM3 i sposoby ich zastosowania
US10822414B2 (en) * 2014-11-11 2020-11-03 Sutro Biopharma, Inc. Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
CN104592388B (zh) * 2015-03-02 2017-05-31 中国人民解放军总医院 一种抗人Tim‑3的单克隆抗体的抗原结合部分
CN107847589B (zh) 2015-04-01 2022-03-29 安奈普泰斯生物有限公司 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体
EP3551659A1 (fr) * 2016-12-08 2019-10-16 Eli Lilly and Company Anticorps anti-tim-3 pour combinaison avec des anticorps anti-pd-l1
JOP20190133A1 (ar) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
JOP20190222A1 (ar) * 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3

Also Published As

Publication number Publication date
AU2017316473A1 (en) 2019-01-31
DOP2019000027A (es) 2019-03-15
JOP20190013A1 (ar) 2019-01-31
CN109563172A (zh) 2019-04-02
ZA201900373B (en) 2020-10-28
CA3035042A1 (fr) 2018-03-01
US10253096B2 (en) 2019-04-09
TW201819419A (zh) 2018-06-01
IL264159A (en) 2019-02-28
WO2018039020A1 (fr) 2018-03-01
EP3504240A1 (fr) 2019-07-03
CN109563172B (zh) 2022-02-08
ES2908916T3 (es) 2022-05-04
PE20190630A1 (es) 2019-04-26
JP2019517999A (ja) 2019-06-27
US20180057591A1 (en) 2018-03-01
AU2017316473B2 (en) 2019-12-19
TWI639616B (zh) 2018-11-01
PH12019500369A1 (en) 2019-11-25
KR20190031528A (ko) 2019-03-26
MX2019002064A (es) 2019-06-06
ECSP19013181A (es) 2019-03-29
SG11201900480YA (en) 2019-02-27
CR20190079A (es) 2019-04-08
CL2019000488A1 (es) 2019-07-12
TN2019000040A1 (en) 2020-07-15
BR112019001589A2 (pt) 2019-07-09
CO2019001646A2 (es) 2019-03-08
EP3504240B1 (fr) 2022-02-16
JP6502590B1 (ja) 2019-04-17
KR102142903B1 (ko) 2020-08-11
NZ749820A (en) 2021-05-28
UA122929C2 (uk) 2021-01-20
TW201900684A (zh) 2019-01-01

Similar Documents

Publication Publication Date Title
MA46041A (fr) Anticorps anti-tim -3
EP3498840A4 (fr) Anticorps anti-lag-3
EP3589313A4 (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA45231A (fr) Anticorps anti-ige
EP3423089A4 (fr) Anticorps anti-tigit
MA47268A (fr) Anticorps anti-gpc3
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA47472A (fr) Anticorps
MA53297A (fr) Anticorps anti-icos
MA46057A (fr) Anticorps anti-ctla4
MA46272A (fr) Anticorps anti-cd27
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3399992A4 (fr) Anticorps autoréticulants
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
MA51134A (fr) Anticorps anti-alpha-synucléine
EP3526251A4 (fr) Anticorps anti-p53
MA42843A (fr) Anticorps anti-cd115
EP3449930C0 (fr) Agent de formation de synapses
EP3336185A4 (fr) Anticorps